Johnson & Johnson Under Pressure As FDA Calls For Pause On COVID Vaccine

WHAT'S NOTABLE: In a statement on CVST or Thrombotic events, Moderna said, "A comprehensive assessment of the totality of the available safety data for mRNA-1273 after over 64.5 million doses administered globally does not suggest an association with cerebral venous sinus thrombosis or thrombotic events."

PRICE ACTION: In morning trading, shares of Johnson & Johnson have dropped almost 3% to $157.25, while Moderna's stock has gained over 8% to $150.68.

1 2 3
View single page >> |

Disclaimer: TheFly's news is intended for informational purposes only and does not claim to be actionable for investment decisions. Read more at  more

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.